Quantcast
Last updated on April 17, 2014 at 12:12 EDT

Latest Triple-negative breast cancer Stories

2014-02-12 12:30:03

WORCESTER, Mass. and TORONTO, Feb. 12, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (GNBT) today announced that recent results from a Phase II study of a novel cancer vaccine designed to prevent relapse in patients who have had breast cancer corroborate prior results from an interim analysis conducted in October of 2011. The Company plans to disclose full results from the Phase II clinical trial at this year's American Society of Clinical Oncology (ASCO)...

Smoking Bad Not Only For Lungs, But Also For Breasts: Study
2014-02-10 13:19:11

[ Watch the Video: Smoking Can Also Give You Breast Cancer ] Brett Smith for redOrbit.com - Your Universe Online Cigarette smoking has frequently been linked to cancers of the respiratory system, but a new study has found that smoking can also greatly increase the risk of a certain breast cancer in women. According to a study recently published in the journal Cancer, young women who smoke a pack per day for a decade or longer have a much greater risk of having the most common kind of...

2014-01-30 23:23:57

Triple Negative Breast Cancer Foundation's Second Annual Campaign on 3-3-14 Supports Survivors, Patients and Research of Lesser-known Breast Cancer Norwood, NJ (PRWEB) January 30, 2014 Kicking off a national campaign of grassroots, online and community events, The Triple Negative Breast Cancer Foundation (http://www.tnbcfoundation.org) announced its Second Annual Triple Negative Breast Cancer Day (http://tnbcfoundation.org/tnbcday2014) will be held on Monday, March 3, 2014 — with...

2014-01-28 23:03:54

An early stage study shows melatonin – a hormone that regulates the body’s sleep and awake cycles – may have the potential to help slow the growth of certain breast cancer tumors, according to researchers from Henry Ford Hospital in Detroit and Foundation for Research Support of the State of São Paulo. Detroit, Michigan (PRWEB) January 28, 2014 An early stage study shows melatonin – a hormone that regulates the body’s sleep and awake cycles – may have the potential to...

Melatonin Therapy May Help Slow Breast Cancer Tumor Growth
2014-01-28 14:19:25

Brett Smith for redOrbit.com - Your Universe Online Produced by the brain in response to darkness and often taken as a sleep aid supplement, melatonin could be effective in slowing the growth of certain breast cancer tumors, according to a new report published in the open-access journal PLOS ONE. More specifically, melatonin may stunt tumor growth and tumor cell production, as well as obstruct the generation of new blood vessels in breast cancer cells that test negative for estrogen...

2014-01-15 08:28:21

Trial Will Compare Investigational Compound's Efficacy and Safety as an Addition to Standard Treatment NORTH CHICAGO, Ill., Jan. 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a Phase 3 clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888) when added to carboplatin, a chemotherapy, in women with early-stage, triple-negative breast cancer. The three-arm trial will compare the addition of veliparib plus...

2014-01-14 08:29:36

SAN FRANCISCO, Jan. 14, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that the Independent Data Monitoring Committee (DMC) created to provide safety oversight for the Company's pivotal clinical study for etirinotecan pegol (NKTR-102) has recommended continuation of the BEACON phase 3 trial, based upon the completion of a planned interim efficacy analysis in accordance with the DMC charter. The BEACON trial is evaluating NKTR-102 versus an agent of physician's...

2014-01-13 08:26:50

To Expand Clinical Trial for Advanced Ovarian Clear Cell Carcinoma ROCKVILLE, Md., Jan. 13, 2014 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of diseases, announced today that it has moved to expand its Phase 2 clinical trial for its drug candidate ENMD-2076 in advanced ovarian clear cell carcinoma (OCCC) with the submission of a new drug global clinical trial application with China's Food and Drug...

2014-01-10 23:03:55

CPIC study finds a correlation between biological subtype and survival. Fremont, CA (PRWEB) January 10, 2014 In a recent study, researchers from the Cancer Prevention Institute of California (CPIC) found that the biological subtype of breast cancer diagnosed in adolescent and young adult women directly affects their risk of dying from the disease. “We have known for a long time that women between the ages of 15 and 39 who have breast cancer are less likely to survive than older women...

2013-12-26 16:21:29

I-SPY 2 Graduates Two Promising Drugs that Show Improved Response for Women with HER2-Positive and Triple-Negative Breast Cancer BETHESDA, Md., Dec. 26, 2013 /PRNewswire/ -- The I-SPY 2 TRIAL, a randomized phase II clinical trial for breast cancer launched through a unique partnership with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and sponsored by QuantumLeap Healthcare Collaborative has graduated the first two drugs from its innovative,...